Global Leading Market Research Publisher QYResearch announces the release of its latest report “Butterfly Wing Indwelling Needle – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global butterfly wing indwelling needle market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for butterfly wing indwelling needle was estimated to be worth US1,340millionin2025andisprojectedtoreachUS1,340millionin2025andisprojectedtoreachUS 1,914 million, growing at a CAGR of 5.3% from 2026 to 2032. This sustained growth is driven by increasing global hospital admission and outpatient procedure volumes, rising prevalence of chronic diseases requiring long-term intravenous (IV) therapy (cancer, diabetes, autoimmune disorders), growing demand for safe and comfortable vascular access devices in pediatric and geriatric populations, and expansion of outpatient infusion centers and home healthcare services.
The butterfly wing indwelling needle is a medical device used for intravenous infusion, injection or blood collection. It has a wing-shaped wing design, which is easy to fix and operate. The needle has a small needle and is suitable for children, the elderly and patients with thin blood vessels. It is often used in situations where long-term intravenous treatment is required. The wing design can provide stable fixation, reduce patient discomfort, and reduce the risk of vascular damage. These winged infusion sets (also known as butterfly needles or scalp vein sets) are distinguished from standard peripheral IV catheters by their flexible wing-like flaps (typically 2-3 cm in length) that allow the clinician to grasp, stabilize, and tape the device securely in place. The combination of small gauge needles (typically 21G-27G) and flexible tubing (10-30 cm) minimizes vessel trauma and dislodgement risk, making butterfly needles the preferred vascular access device for difficult venous access, fragile veins, and procedures requiring extended indwelling time (several hours to days of intermittent or continuous infusion).
For comprehensive market segmentation, catheter length comparisons, and application intelligence, industry stakeholders can access the complete dataset.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6092921/butterfly-wing-indwelling-needle
Market Segmentation by Catheter Length and End-User
The butterfly wing indwelling needle market is segmented as below to reflect distinct clinical applications and anatomical sites:
Selected Key Players (Partial List):
B Braun, Terumo, BD, NIPRO Medical, Smiths Medical, Medtronic, Hindustan Syringes & Medical Devices (HMD), Sungwon Medical, KDL, WEGO Group, TuoRen Group, Biop Medical, Sinomed
Segment by Catheter Length
- Short Catheter (10-20mm) – For superficial veins (hand, forearm, scalp in infants); used for short-term infusion, blood draw, and patients requiring limited insertion depth
- Long Catheter (25-50mm) – For deeper or larger peripheral veins (antecubital fossa, cephalic vein, basilic vein); used for longer indwelling duration and higher flow rates
Segment by End-User
- Hospital (inpatient units, emergency departments, operating rooms, oncology infusion centers)
- Clinic (outpatient clinics, ambulatory infusion centers, physician offices, home healthcare)
Technical Deep Dive: Catheter Length Selection and Clinical Applications
A critical clinical consideration in selecting a butterfly wing indwelling needle is the catheter length relative to vein depth and intended indwelling duration. Short catheter (10-20mm) butterfly needles (typically 21G-25G) are designed for superficial veins in the hand, dorsal forearm, and (in infants) the scalp, where vein depth is 2-5 mm from skin surface. Short catheters minimize the risk of posterior vein wall puncture (the needle tip exiting through the far vein wall) and are preferred for (1) pediatric patients (limited vein size, thin skin), (2) geriatric patients with fragile, rolling, or superficial veins, (3) patients with edema or obesity where superficial veins remain accessible, and (4) short-term infusions (<24 hours) or single blood draws. Short catheter butterfly needles are the most commonly used configuration, representing approximately 60-65% of market volume.
Long catheter (25-50mm) butterfly needles (typically 18G-22G) are designed for deeper veins in the antecubital fossa, cephalic vein, and basilic vein (vein depth 6-15 mm). Longer catheters provide additional anchorage within the vein lumen, reducing dislodgement risk during patient movement, and are preferred for (1) long-term intravenous therapy (intermittent or continuous infusions over 24-72 hours), (2) higher flow rate infusions (blood transfusions, rapid fluid resuscitation, chemotherapy), (3) patients with robust veins where a longer catheter provides greater stability, and (4) situations where the insertion site will be covered by clothing or dressings requiring secure fixation.
A notable technical innovation has been integrated safety mechanisms to reduce needlestick injuries (NSIs) during butterfly needle use. Historically, butterfly needles had higher NSI rates than standard IV catheters because of device design (long tubing, two-handed disassembly). In October 2025, BD launched the Nexiva Butterfly with passive safety shield—a sliding mechanism that automatically covers the needle upon withdrawal. The device has been shown in a multisite study (7 hospitals, n=12,000 butterfly needle placements) to reduce NSIs by 76% compared to non-safety butterfly needles and 42% compared to manually activated safety designs. Regulatory guidance (OSHA, NIOSH) increasingly recommends safety-engineered sharp devices for all vascular access, driving adoption of mechanically activated or passive safety butterfly needles.
Another technical consideration is catheter material and tip design. Traditional butterfly needles use stainless steel cannulae (rigid, single use). However, over-the-needle catheter designs (where a flexible PTFE or FEP catheter is advanced over a stainless steel stylet, then the stylet is removed) offer extended indwelling capability with lower phlebitis rates. Over-the-needle butterfly-style devices (e.g., BD Insyte Autoguard, B Braun Introcan Safety) combine butterfly wings with flexible IV catheters, offering the handling benefits of wing design with the dwell advantages of flexible catheters. These hybrid devices command premium pricing (20-40% higher) but are gaining share in oncology and long-term infusion settings.
Recent Clinical and Market Developments
The butterfly wing indwelling needle market has experienced significant developments in 2025-2026. In November 2025, the Infusion Nurses Society (INS) updated its “Infusion Therapy Standards of Practice,” including specific recommendations for butterfly needle use: (1) aseptic non-touch technique (ANTT) for insertion, (2) stabilization with sterile transparent dressings (not tape alone), (3) replacement interval not to exceed 96 hours for catheter-type butterfly devices, (4) immediate removal upon signs of phlebitis or infiltration. These standards are expected to drive demand for clinically validated, safety-engineered devices with documented lower complication rates.
In January 2026, B Braun launched the Introcan Safety Butterfly 2.0, featuring a novel wing lock stabilization mechanism—the wings lock into a fixed position after insertion, preventing accidental retraction and reducing device movement by approximately 60% compared to conventional wing designs (testing data, n=200 simulated insertions). The device includes a passive safety shield (needle retracts into the wings) and color-coded wing/needle combinations (21G=blue, 23G=light blue, 25G=orange) for easy size identification.
Product innovation continues in specialty butterfly needle applications. In October 2025, Medtronic received FDA 510(k) clearance for the PediaWing 24G butterfly needle specifically designed for neonatal and pediatric patients. Features include: (1) 8mm ultra-short catheter (for scalp and hand veins in neonates), (2) transparent wing material for visible flashback visualization, (3) integrated extension line (20 cm) with small-bore tubing (reducing dead space to <0.2 mL), and (4) passive safety shield. The device is positioned to capture a share of the estimated 15 million neonatal/pediatric IV placements in the U.S. annually.
Regional market dynamics reveal that North America accounts for approximately 45% of global butterfly wing indwelling needle demand, driven by high healthcare utilization, safety-engineered device adoption (OSHA compliance), and group purchasing pricing power. Europe represents approximately 30%, with Germany, France, and the UK as major markets, and increasing emphasis on needlestick prevention (EU Directive 2010/32/EU implementation). Asia-Pacific is the fastest-growing region (CAGR 6-8%), driven by expanding hospital capacity in China (2,000+ new hospitals planned through 2030), India (rising healthcare access, vaccination campaigns), and Southeast Asia. Chinese domestic manufacturers (WEGO Group, TuoRen Group, KDL, Biop Medical, Sinomed) have captured significant market share through competitive pricing (40-60% below international brands) and domestic regulatory approvals (NMPA). However, safety-engineered device adoption in Asia-Pacific lags behind North America and Europe (estimated 25-35% safety device penetration vs. >80% in U.S. hospitals), representing a substantial future growth opportunity.
Industry Sub-segment Divergence: Hospital vs. Clinic and Home Healthcare Applications
The butterfly wing indwelling needle market divides meaningfully between hospital and clinic/home healthcare settings. Hospital users (approximately 75% of demand) prioritize (1) vascular access success rates (first-attempt success, especially in difficult venous access), (2) safety-engineered features (passive safety designs preferred), (3) bulk procurement pricing (standardized devices across departments), and (4) compatibility with hospital IV administration sets and infusion pumps. Hospitals typically stock multiple gauges (22G-25G) and both short (for pediatric/geriatric) and long (for general adult) catheter lengths.
Clinic and home healthcare users (approximately 25% of demand) prioritize (1) ease of use for single-practitioner settings, (2) patient comfort and cosmetic appearance (many home healthcare patients self-administer IV therapies including antibiotics, hydration, chemotherapy, or immunoglobulin infusions), (3) smaller package sizes (clinics and home care agencies cannot purchase hospital pallet volumes), and (4) lower per-unit cost (most clinic/home payers operate on tighter margins). A distinctive exclusive observation: the home infusion market segment is growing at 10-12% annually, driven by patient preference for at-home therapy, hospital-at-home programs, and payor pressure to reduce facility-based infusion costs. Home infusion nurses preferentially use butterfly wing indwelling needles for peripheral IV access because of the stability provided by wing fixation (patient movement, sleep) and the smaller gauge options for fragile veins (24G-27G). This segment is underserved by safety-engineered devices, as many passive safety butterfly needles are sold in quantities (100-200 boxes) too large for home health agencies. In response, BD and Medtronic introduced 25-unit boxes in Q4 2025 specifically targeting the home infusion channel.
Future Outlook and Strategic Recommendations
As the butterfly wing indwelling needle market evolves toward 2032, three strategic directions emerge: (1) continued migration toward passive, integrated safety mechanisms (needle retraction) as regulatory and purchasing requirements mandate sharps injury prevention for all vascular access devices; (2) development of ultrasound-guided butterfly needle configurations (extended length, enhanced echogenicity) for difficult venous access patients (obesity, edema, IV drug use history, multiple prior hospitalizations) where blind insertion success rates are low; (3) expansion of drug-eluting or antimicrobial-coated catheters (silver, chlorhexidine) to reduce catheter-related bloodstream infections in extended-dwell applications. For hospitals and healthcare facilities, selecting a butterfly wing indwelling needle with (1) passive safety activation to ensure user compliance, (2) catheter length appropriate for patient populations served (short catheters for pediatric/geriatric, long catheters for adult general medical/surgical), (3) visible flashback chamber for insertion confirmation, and (4) competitive bulk pricing with vendor-managed inventory is essential. For clinic and home healthcare providers, prioritizing smaller packaging, ease of training (for staff and patient caregivers), and compatibility with existing IV administration components offers optimal value. For intravenous therapy device manufacturers, differentiation will increasingly come from safety-engineering, ultrasound visibility enhancements, patient comfort features (thin-wall needle geometry, silicone-free coatings), and regulatory clearance in both developed (FDA/CE) and high-growth emerging markets (NMPA Japan Taiwan Brazil). By 2028, it is anticipated that passive safety butterfly needles will exceed 50% of global hospital market volume (up from approximately 25-30% in 2025), driven by regulatory convergence and group purchasing safety requirements.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
